Watch this very interesting video hereShare This Page
Watch this very interesting video hereShare This Page
Anthony White went through hell a few years ago. Now that he’s back
in good health, he wants to share his story with the world and tell
people that life is for the living, and organ transplants are the best
kind of gift.
The 67-year-old British Columbia native had
hepatitis B but was otherwise in pretty good health. He played baseball
and he still knew how to drink. He was taking Heptovir to manage the
virus and some blood work came back in 2008 that there was no sign of hep B.
thought that he had beaten it. He stopped taking the drug, a mistake he
now admits. A couple of drinks at Christmas did much damage, he would
soon find out.
NEW YORK (Reuters Health) – In HIV patients with hepatitis C, compensated cirrhosis should not be considered a contraindication to therapy with pegylated interferon (peg-IFN) and ribavirin, researchers say.
As is the case in patients without HIV, peg-IFN plus ribavirin is more effective against hep C in HIV patients who are free of cirrhosis, the researchers reported online September 5th in Clinical Infectious Diseases.
THURSDAY, Sept. 27 (HealthDay News) — Many U.S. babies born to
mothers infected with hepatitis B do not receive recommended follow-up
testing after vaccination, a new study finds.
Infants born to mothers infected with hepatitis B should
receive the hepatitis B vaccine and hepatitis B immune globulin within
12 hours of birth, the federal Advisory Committee on Immunization
Practices recommends. Infants should complete the three-dose hepatitis B
series, which is up to 95 percent effective in preventing infections.
The 2012 UK Prix Galien Innovative Product Award was shared
between Janssen and Merck & Co for their respective drugs to treat
The prize, which recognises innovative medicines recently launched or
granted a new indication in the UK, was jointly awarded to Janssen’s
Incivo (telaprevir) and Merck’s Victrelis (boceprevir), both of which
represent a major advance in the treatment of the infection.
“Hepatitis C infection is a perfect of example where the
pharmaceutical industry can demonstrate and justify its place in
healthcare by innovating for change and showing real gains to the
world,” said chair of the judging panel, Professor Sir Michael Rawlins,
who is also chair of the National Institute for Health and Clinical
This is also the story of the absolute lack of understanding
displayed regularly by some media personnel about the process of
scientific innovation in the modern day
Let us think for a
moment about a physician who specialises in Infectious Diseases (ID) and
currently practices in Pakistan. Her total training time to become a
fully qualified, American board certified ID consultant would be roughly
11 years: five or six years of medical school education in Pakistan,
three years of Internal Medicine residency training in the US and then
two additional years in the Infectious Disease fellowship programme.
During these years of extraordinary hardship, she was also able to
publish a couple of review articles in a medical journal on viral
illnesses. Her area of interest had always been the treatment of
Hepatitis C — a chronic viral infection of the liver — in Pakistan and
most of her patients therefore, in the present practice, carry that
infection. She treats her patients according to international standards;
she follows the guidelines, keeps up with their recommendations and has
an overall 40-50 percent cure rate, a little lower than the
international success rate.
One day, she was invited by a
renowned television anchor in his show to discuss the treatment options
available in Pakistan for Hepatitis C. (The chronic viral infection now
is endemic in our country and almost eight to ten percent of the total
population has been infected by it.) He reassured her that she was the
only qualified specialist in the town and her expertise could save many
lives and help the population at large to prevent future exposure.
Additionally, he spoke highly about her publications and admired her
professionalism. She must have been flattered to hear that her
contribution was finally recognised and excited to be able to talk on
the public forum. She gladly accepted the invitation and started
preparing her presentation. She wanted to emphasise disease prevention,
the latest research, current concepts and the different treatment
options in the programme.
Just three months after Achillion started a Phase Ia study for
ACH-3102, which was used for a classic safety check, investigators
ramped up a Ib trial with 14 patients. Today it reported that the NS5A
inhibitor, billed as a next-gen competitor for the oral, interferon-free
combo treatments now in the clinic, produced a significant reduction in
viral load after a range of single doses were tested. A mean maximum
3.74 log reduction in HCV RNA was recorded for genotype 1a patients,
with resistant variants also responding.
With the 14-day efficacy results completed, Achillion has already
jumped into a 12-week Phase II study of 3102 combined with ribavirin for
genotype 1b. And investigators will test the sustained virologic
response level, with that data coming in the fourth quarter of this
year. Altogether, Phase Ia through an initial Phase II is being executed
in less than five months, a pace rarely matched in the slow-moving drug
development. Achillion also has its lead NS3 protease, ACH-1625
(sovaprevir), in mid-stage studies.
Incarcerated patients with chronic hepatitis C virus
(HCV) infection are just as likely to respond to treatment for the
disease as patients in the community, according to findings published in
the October issue of Hepatology,
a peer-reviewed journal of the American Association for the Study of
Liver Diseases. The study from the University of Wisconsin School of
Medicine and Public Health (SMPH) in Madison found that HCV patients in
prison were just as likely to achieve a sustained viral response (SVR)
as non-incarcerated patients.
Medical evidence reports that chronic HCV is the
leading cause of end-stage liver disease (ESLD) and liver disease
mortality in the U.S. Further studies have shown the risk of developing
cirrhosis due to chronic HCV ranges between 5 and 25 percent over a 25
to 30 year period. Consequences caused by chronic HCV are major public
health concerns within the U.S. prison system, with research conducted
by the Centers for Disease Control and Prevention (CDC) estimating up to
31 percent of U.S. inmates have chronic HCV, compared to just two
percent of the general population in this country.
“Given that a history of intravenous drug use is
more frequent among inmates, there is a higher prevalence of HCV
infection in the prison population,” explains lead author Dr. Michael
Lucey, Chief of the Division of Gastroenterology and Hepatology at the
SMPH. “HCV treatment during incarceration provides an opportunity to
make a significant improvement to public health.”
Incarcerated and non-incarcerated patients with HCV
who were seen at the University of Wisconsin Hepatology or Infectious
Diseases Clinic between January 2002 and December 2007, were evaluated
for antiviral therapy. Researchers identified 521 general-population
patients and 388 from the prison population who were evaluated for HCV
Results show that 61 percent of non-incarcerated and
60 percent of incarcerated patients received treatment with pegylated
interferon and ribavirin. Those from the prison population were more
likely to be African-American males with a history of alcohol or
intravenous drug use. The team reported that SVR was achieved in 43
percent of prisoners compared to 38 percent of patients in the
“Our findings highlight the effectiveness of
antiviral therapy in HCV-infected prisoners, and show that it is as
successful as treatment for HCV patients in the general population,”
concludes Dr. Lucey. “With previous studies citing poor results of HCV
treatment in high-risk groups on an outpatient basis, a correctional
setting may be an optimal setting for treatment that will help curb the
hepatitis C public health crisis.”
This research was funded by the American Cancer
Society Research Scholar Grant, the National Institutes of Health (NIH)
Clinical and Translational Science Award, and by the Clinical and
Translational Science Award (CTSA) program of the National Center for
Research Resources at NIH.
Author Contact: To arrange an interview with
Dr. Michael Lucey, please contact Mike Klawitter with University of
Wisconsin Hospital and Clinics Public Affairs in Madison, WI at email@example.com or at +1 608-265-8199.
About the Journal
Hepatology is the premier publication in the field of liver
disease, publishing original, peer-reviewed articles concerning all
aspects of liver structure, function and disease. Each month, the
distinguished Editorial Board monitors and selects only the best
articles on subjects such as immunology, chronic hepatitis, viral
hepatitis, cirrhosis, genetic and metabolic liver diseases and their
complications, liver cancer, and drug metabolism. Hepatology is published on is published by Wiley on behalf of the American Association for the Study of Liver Diseases (AASLD). For more information, please visit http://wileyonlinelibrary.com/journal/hep.
Founded in 1807, John Wiley & Sons, Inc. has been a valued source of
information and understanding for more than 200 years, helping people
around the world meet their needs and fulfill their aspirations. Wiley
and its acquired companies have published the works of more than 450
Nobel laureates in all categories: Literature, Economics, Physiology or
Medicine, Physics, Chemistry, and Peace.
Wiley is a global
provider of content and content-enabled workflow solutions in areas of
scientific, technical, medical, and scholarly research; professional
development; and education. Our core businesses produce scientific,
technical, medical, and scholarly journals, reference works, books,
database services, and advertising; professional books, subscription
products, certification and training services and online applications;
and education content and services including integrated online teaching
and learning resources for undergraduate and graduate students and
lifelong learners. Wiley’s global headquarters are located in Hoboken,
New Jersey, with operations in the U.S., Europe, Asia, Canada, and
Australia. The Company’s Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.